my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
24-05-2012: Phagenesis Ltd has been awarded c. £1 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community. The Phagenesis technology is designed to treat patients who are dysphagic following a stroke.
Dysphagia affects more than one million stroke victims in Europe and North America per year. Dysphagic patients can suffer from malnutrition and can develop pneumonia as a result of inhaling solids, liquids or their own saliva. Currently, there is no generally accepted treatment for the condition and patients typically have to be fed puréed food and thickened liquids or be fed through a tube, which can severely limit their quality of life.
Phagenesis has developed the world’s first clinically-proven device to treat dysphagia in stroke patients in the first few weeks while they are hospitalised. With the help of the Wellcome Trust, Phagenesis is now developing and testing a new version of its device to treat patients suffering from long-term dysphagia.
Daniel Green, CEO of Phagenesis, said: “Our technology can make a significant difference to patients in the hospital who have this difficult-to-treat condition. We believe this benefit can be extended more widely to people outside the hospital setting. We are delighted to have the support of the Wellcome Trust to adapt our technology and reach these patients and improve their quality of life.”
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Phagenesis Launches First Treatment for Acute Dysphagia
Phagenesis launches the world's first approved treatment for acute dysphagia following stroke. The Phagenyx™ system delivers calibrated electrical stimulus to the throat (oropharynx) for 10 minutes a day for three consecutive days to patients who suffer from dysphagia – the inability to swa ... more
Phagenesis Wins c. £1 million Translation Award by Wellcome Trust to Expand Dysphagia Treatment
Phagenesis Ltd has been awarded c. £1 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community. The Phagenesis technology is designed to treat patients who are dysphagic following a stroke.Dysphagia affects more than one mil ... more
Phagenesis closes €7million Series B financing round
Phagenesis Ltd announced that it has closed a €7 million Series B funding round designed to accelerate the company’s development plans. The investment is led by Inventages, one of the world’s largest life science funds specialised in treatment solutions for chronic diseases. Existing shareh ... more
Biocartis collaborates with Philips and Wellcome Trust in oncology diagnostics
Biocartis announces that its researchers, in collaboration with researchers at the Wellcome Trust Sanger Institute and at Philips Research, are developing a novel workflow for extraction and amplification & detection of tumor DNA on Biocartis diagnostic platforms. Biocartis retains its full ... more
Phagenesis Wins c. £1 million Translation Award by Wellcome Trust to Expand Dysphagia Treatment
Phagenesis Ltd has been awarded c. £1 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community. The Phagenesis technology is designed to treat patients who are dysphagic following a stroke.Dysphagia affects more than one mil ... more
Canbex Therapeutics receives £1.75 million Translation Award from the Wellcome Trust
Canbex Therapeutics Ltd. announced today that it has received a Translation Award of up to 1.75 million ($2.8 million) from the Wellcome Trust to support development of a drug for the treatment of the debilitating muscle spasms associated with multiple sclerosis and potentially other disord ... more
The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending around £650 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research an ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
